Endocyte (ECYT) Upgraded to “Outperform” by Cowen
Cowen upgraded shares of Endocyte (NASDAQ:ECYT) from a market perform rating to an outperform rating in a report released on Tuesday morning, Marketbeat reports.
Other equities research analysts have also issued reports about the company. Zacks Investment Research upgraded Endocyte from a sell rating to a hold rating in a research report on Friday, February 9th. ValuEngine lowered Endocyte from a sell rating to a strong sell rating in a research report on Thursday, December 21st.
Shares of Endocyte (NASDAQ:ECYT) opened at $6.50 on Tuesday. The firm has a market capitalization of $276.74, a P/E ratio of -5.12 and a beta of 1.02. Endocyte has a 1 year low of $1.17 and a 1 year high of $6.70.
In related news, insider Philip S. Low sold 50,511 shares of Endocyte stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $4.41, for a total transaction of $222,753.51. Following the sale, the insider now directly owns 354,050 shares in the company, valued at $1,561,360.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 14.86% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ECYT. AXA bought a new stake in shares of Endocyte during the fourth quarter valued at approximately $101,000. Dimensional Fund Advisors LP boosted its position in shares of Endocyte by 34.1% during the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 25,003 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Endocyte by 46.5% during the fourth quarter. Bank of New York Mellon Corp now owns 51,313 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 16,283 shares in the last quarter. EAM Investors LLC bought a new stake in shares of Endocyte during the fourth quarter valued at approximately $420,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Endocyte by 1,064.3% during the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after purchasing an additional 393,975 shares in the last quarter. Institutional investors own 19.45% of the company’s stock.
Endocyte Company Profile
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.